Skip to main content

Month: January 2026

Leapfrog Acquisition Corporation Announces the Separate Trading of Its Class A Ordinary Shares and Warrants, Commencing on or About January 26, 2026

Summit, NJ, Jan. 20, 2026 (GLOBE NEWSWIRE) — Leapfrog Acquisition Corporation (the “Company”) announced today that, commencing on or about Monday, January 26, 2026, holders of the units sold in the Company’s initial public offering may elect to separately trade the Class A ordinary shares and warrants included in the units. The Class A ordinary shares and warrants that are separated are expected to trade on the Nasdaq Global Market (“Nasdaq”) under the symbols “LFAC” and “LFACW”, respectively. Any units not separated will continue to trade on Nasdaq under the symbol “LFACU.” No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Each holder of units will need to have its broker contact Odyssey Transfer and Trust Company, the Company’s transfer agent, in order to separate the units...

Continue reading

Protext Mobility, Inc. (OTC: TXTM) is thrilled to share a transformative update, advancing uplisting readiness with a preliminary Deloitte engagement

FORT LAUDERDALE, Fla., Jan. 20, 2026 (GLOBE NEWSWIRE) — Protext Mobility, Inc. (OTC: TXTM) (“Protext” “TXTM” or the “Company”) is thrilled to share a transformative update that underscores its strategic execution, operational excellence, ESG leadership, and forward momentum, reinforcing shareholder confidence and highlighting the bright path ahead. TXTM has entered a preliminary engagement with Deloitte, one of the world’s top five accounting and advisory firms, regarding an independent valuation of the Company’s enterprise, as part of its uplisting-readiness sequence. The rationale: This valuation is designed not only to support uplisting, but also to demonstrate that TXTM’s current stock price significantly undervalues the company’s franchise value, including:The monetization of its proprietary technology, including kettle...

Continue reading

ALSTOM S.A: Alstom’s third quarter 2025/26: Record orders, Reaching €100bn backlog, FY 2025/26 outlook confirmed

Outstanding commercial momentum driving backlog to above €100bnOrder intake of €9.6 billion in Q3 and €20.0 billion in the first 9 months Book-to-bill ratio1 of 1.4 for the Group and 1.8 for Rolling Stock over the first 9 monthsSales growth trending towards full-year outlookGroup sales at €4,792 million in Q3, up 2.6%, of which 5.9% on an organic1 basis Group sales at €13,851 million in the first 9 months, up 3.0%, of which 7.2% on an organic1 basisFY 2025/26 outlook and mid-term ambitions confirmed        20 January 2026 – Alstom, global leader in smart and sustainable mobility, reports commercial and financial performance for the third quarter of fiscal year 2025/26 (from 1 October to 31 December 2025), with orders more than doubling to €9.6 billion compared to the same period last fiscal year and sales increasing by...

Continue reading

Closed-End Fund Education in Closed-End Corner Videos

RYE, N.Y., Jan. 20, 2026 (GLOBE NEWSWIRE) — Investors looking to learn about the often-overlooked asset class of closed-end funds are invited to visit The Closed-End Corner on Gabelli TV and YouTube. The Closed-End Fund Corner has produced a series of educational videos on topics currently threatening Closed-End Funds. To view the videos, please click on the link below: https://gabelli.com/insights/gabelli-media/gabelli-closed-end-corner/ Videos include: Back To The Future With Closed-End Funds Looks at the history of Closed-End Funds and traces their remarkable growth since 1985, the year Back To The Future premiered. At that time, closed-end funds Net Asset Values were only published weekly in newspapers and numbered about 25 with some dating back to before the depression. Short-Term Value Extraction vs. Long-Term Value Creation...

Continue reading

WestKam Gold Corp. Announces Prospecting and Soil Sampling Results for Will Property, Mt. Williams, B.C.

Vancouver, B.C. , Jan. 20, 2026 (GLOBE NEWSWIRE) — WestKam Gold Corp. (the “Company” or “WestKam”) is pleased to announce the results of a helicopter-assisted, soil sampling survey completed on the Will Claim.  The sampling program was conducted in late September 2025 to test gossanous areas interred to contain altered ultramafics on the Company’s 100%-owned Will Project, located on Mt. Williams near Goldbridge, British Columbia. The Will Project encompasses 1,142.47 hectares of highly prospective terrain and is in good standing through January 30, 2027. The 2025 exploration program focused on a zone of listwanite alteration in the upper reaches of Mt. Williams, an area with geological characteristics conducive to gold and antimony mineralization. The targeted alteration zone is situated on trend with the Minto-Olympic shear zone,...

Continue reading

HII Selected to Compete on $25.4 Billion Microelectronics Multi-Award Contract

MCLEAN, Va., Jan. 20, 2026 (GLOBE NEWSWIRE) — HII (NYSE: HII) announced today that its Mission Technologies division is among 12 companies included on a 10-year, $25.4 billion Advanced Technology Support Program V (ATSP5) multiple award indefinite delivery/indefinite quantity contract to provide engineering solutions for electronics and software problems. Awarded by the Defense Microelectronics Activity, ATSP5 is used across the U.S. Department of Defense and other civilian federal agencies to rapidly obtain advanced microelectronics, engineering, prototyping and technology modernization support. The contract provides rapid, flexible access to advanced microelectronics technologies, solves operational problems caused by obsolescence and accelerates deployment. “Delivering a trusted, assured supply of microelectronics directly impacts...

Continue reading

Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab

BOSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the peer-reviewed publication of its open-label study in patients with non-active secondary progressive multiple sclerosis (na-SPMS) in Neurology Neuroimmunology & Neuroinflammation, a prestigious journal of the American Academy of Neurology. The publication, titled “Nasal Foralumab for the Treatment of Progression Independent of Relapses in Patients with Non-active Secondary Progressive Multiple Sclerosis,” details the comprehensive positive results previously announced by the Company on May 6, 2025. This marks the first study to integrate TSPO-PET imaging, proteomics, and clinical assessments in...

Continue reading

Rezolve Ai Announces $250 Million Registered Direct Offering led by Existing and New Fundamental Institutional Investors

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) — Rezolve Ai (NASDAQ: RZLV), a leader in Agentic Commerce and AI-powered customer engagement, today announced that it has entered into securities purchase agreements led by existing and new fundamental institutional investors for the purchase and sale of 62,500,000 ordinary shares at a purchase price of $4.00 per share, pursuant to a registered direct offering, resulting in gross proceeds of approximately $250 million, before deducting placement agent commissions and other offering expenses. The closing of the offering is expected to occur on or about January 21, 2026, subject to the satisfaction of customary closing conditions.  The Company intends to use the net proceeds from the offering for accelerated investment into its sales organization, potential accretive M&A opportunities...

Continue reading

Cosmos Health Announces Accelerating Customer Growth, Improving Unit Economics and Robotic Expansion Supporting $40M in Additional Annual Revenue

CHICAGO, Jan. 20, 2026 (GLOBE NEWSWIRE) — Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced continued operational growth and infrastructure expansion at Cosmofarm, its pharmaceutical distribution subsidiary in Greece. During 2025, Cosmofarm added nearly 100 new pharmacy customers, representing a weighted average increase of approximately 20% in its active customer base. This growth was accompanied by improved unit economics, with annual revenue per customer increasing by approximately 12% and profitability per customer improving by approximately 14%, driven by enhanced route density, optimized order execution, and increasing operational leverage. Based on current onboarding activity and demand trends, management expects...

Continue reading

Changes in the management board of Baltic Horizon Capital AS

Baltic Horizon Capital AS, the management company of Baltic Horizon Fund, hereby informs of changes in the management board. Edvinas Karbauskas has been proposed for appointment as a member of the management board of Baltic Horizon Capital AS. Edvinas will commence his employment with Baltic Horizon Capital AS starting from 2 February 2026 and, after approval of the Estonian Financial Supervision and Resolution Authority, will become member of the management board and Co-fund Manager of Baltic Horizon Fund together with Tarmo Karotam, the current Fund Manager. Edvinas is expected to rejoin the management board, bringing with him valuable continuity and experience as he previously served as a board member of Baltic Horizon Capital AS from January 2023 to June 2024, during which time he held the position of co-fund manager. Since stepping...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.